Novartis opens production site in the US
Select your language
Generated with artificial intelligence.
Listening:
Novartis opens production site in the US
Basel-based giant Novartis is opening a new radioligand therapy production site in California. This is part of the $23 billion (CHF18.5 billion) investment package in the United States already announced by the company.
+Get the most important news from Switzerland in your inbox
The Carlsbad plant is the third site dedicated to this type of cancer treatment in the US, according to a press release issued on Monday by the pharmaceutical group.
The facility “expands production capacity to meet future demand”, according to Novartis, which says it also guarantees on-time delivery to virtually all patients across the US. The company is planning other sites in Florida and Texas.
+ How pharma became Switzerland’s Achilles heel in the US
The plant south of Los Angeles is part of Novartis’s $23 billion investment plan in the United States.
At the end of September, US President Donald Trump announced new 100% tariffs on medicines, unless the laboratories manufacture their treatments on US soil.
+ Switzerland braces for 100% US medicine tariff
Translated from French by DeepL/ts
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
External Content
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.